| Literature DB >> 25295852 |
Guido F Pauli1, Shao-Nong Chen, Charlotte Simmler, David C Lankin, Tanja Gödecke, Birgit U Jaki, J Brent Friesen, James B McAlpine, José G Napolitano.
Abstract
In any biomedical and chemical context, a truthful description of chemical constitution requires coverage of both structure and purity. This qualification affects all drug molecules, regardless of development stage (early discovery to approved drug) and source (natural product or synthetic). Purity assessment is particularly critical in discovery programs and whenever chemistry is linked with biological and/or therapeutic outcome. Compared with chromatography and elemental analysis, quantitativeEntities:
Mesh:
Year: 2014 PMID: 25295852 PMCID: PMC4255677 DOI: 10.1021/jm500734a
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446
Figure 1Application of the relative (100%) qHNMR method (see also S2, Supporting Information). A commercial sample of quercetin (Q; declared purity >99%; 24.67 mg/mL [not required for purity calculation] in DMSO-d6, 600 MHz) was analyzed. A structurally related compound, kaempferol (K), was identified as an impurity. On the basis of the relative integral ratios, the content of quercetin and kaempferol in the sample was determined as 87.8% and 12.2% w/w, respectively.
Figure 2Application of the internal calibration method for absolute qHNMR analysis (see also S3, Supporting Information). A commercial sample of (+)-catechin (5.33 mg/mL in DMSO-d6, 600 MHz; declared purity >96%) was analyzed. Dimethylsulfone (DMSO2, 99.4% pure) was added to the sample as internal calibrant using a stock solution (2.28 mg/mL; final concentration in the sample 0.380 mg/mL). The content of (+)-catechin in the sample was established as 98.2% w/w.
Proposed Standardized Acquisition Parameters
| temperature | Run experiments at 298 K. |
| flip angle | (a) Determine the requirements and best balance for quantitative
accuracy and limits of detection (LOD) and quantitation (LOQ). As
a general rule, smaller flip angles enable faster signal averaging
for increased |
| (b) If a 90° pulse experiment is used, determine the pulse width by defining the null at 360° and applying the equation: pw90 = 1/4 × pw360. | |
| acquisition time and spectral width | Choose an acquisition time of 4 s. The acquisition time, spectral width, and number of data points are highly related parameters. We recommend the use of a wide spectral window (20–30 ppm width; centered at ca. 5–10 ppm). As the acquisition time and spectral width are already defined, the actual number of data points will be automatically established by the spectrometer. |
| relaxation | Determine the longest longitudinal
relaxation time ( |
Proposed Standardized Processing Parameters
| window function | Our in-house optimized conditions consist of Lorentzian-to-Gaussian apodization, with line broadening of −0.3 and Gaussian factor of 0.05. |
| zero filling | 2- to 3-fold zero filling, depending on resulting |
| phasing | Careful manual phasing for best reproducibility. |
| baseline correction | Apply best available baseline correction method, depending on the software used. The goal is to obtain a visually flat baseline at zero intensity for accurate integration. |
| integration | (a) For pure compounds with nonoverlapping signals: integration areas based on at least 5 × fwhh. Peak heights may also be used, although different processing parameters are required to ensure a quantitative outcome. |
| (b) For mixtures with extensive signal overlap: use curve fitting and, alternatively, computational approaches such as 1H iterative full spin analysis (HiFSA) for unambiguous identification of chemical components. |
Figure 4Application of an externally calibrated solvent signal as internal calibrant for absolute qHNMR analysis. A commercial sample of daidzein (17.78 mg/mL in DMSO-d6, 600 MHz), which was marketed as 97% pure (by LC–MS), was analyzed. The content of residual protonated DMSO-d5 in the DMSO-d6 lot was established using the internal calibration qNMR method with a certified DMSO2 standard as calibrant (see also S5, Supporting Information). The content of daidzein in the commercial sample was established as 78.4% w/w. Analysis of the qHNMR spectrum also revealed the presence of significant amounts of dimethylformamide (DMF) of 21.4% w/w. This translates into an almost equimolar ratio of daidzein/DMF (1.054:1.000), which is consistent with a daidzein solvate from a glycoside hydrolysis protocol (HCl/DMF), containing 51.3. mol % daidzein rather than the labeled pure aglycone.